A a method for identifying solid tumors suitable for treatment using inhibitors of alternative (ALT) non-homologous end joining (NHEJ) factors.
This research shows that an ALT NHEJ pathway is upregulated in breast cancer cell lines that are either intrinsically resistant or have acquired resistance to antiestrogen therapies and that these cell lines are hypersensitive to DNA repair inhibitors that target the ALT NHEJ pathway. The results show that ALT NHEJ is a novel therapeutic target in breast cancers that are resistant to frontline therapies and changes in NHEJ protein levels serve as biomarkers to identify candidates for this therapeutic approach.
According to the National cancer institute’s SEER Cancer Statistics review, it is estimated that 226,870 women will be diagnosed with cancer in 2012. The review also states that the survival rate is only 82.5%. Although the majority of breast cancers are estrogen-dependent and effective antiestrogen therapies have been developed, there is an urgent need to develop new and improved therapeutic strategies for patients whose disease is refractory to antiestrogen therapies. Alterations in the network of pathways that respond to DNA damage and maintain genome stability are presumed to underlie the genomic instability and increased sensitivity of cancer cells to cytotoxic DNA damaging agents used in cancer treatment. These abnormalities are potential targets for the development of therapeutics that either alone or in combination with cytotoxic DNA damaging agents will specifically enhance killing of cancer cells.
Researchers have developed a method for identifying solid tumors suitable for treatment using inhibitors of alternative (ALT) non-homologous end joining (NHEJ) factors. This research shows that an ALT NHEJ pathway is upregulated in breast cancer cell lines and tumors that are either intrinsically resistant or have acquired resistance to antiestrogen therapies. These cell lines are hypersensitive to DNA repair inhibitors that target the ALT NHEJ pathway demonstrating that ALT NHEJ is a novel therapeutic target in breast cancers that are resistant to frontline therapies and that changes in NHEJ protein levels serve as biomarkers to identify candidates for this therapeutic approach.
As the technology-transfer and economic-development organization for the University of New Mexico, STC.UNM protects and commercializes technologies developed at the University of New Mexico (UNM) by filing patents and copyrights and transferring the technologies to the marketplace. We connect the business communication (companies, entrepreneurs and investors) to these UNM technologies for licensing opportunities and the creation of startup companies. Visit www.stc.unm.edu.
由于技术保密工作限制,技术信息无法完全展现,请通过邮箱或短信联系我们,获取更多技术资料。
non-homologous end joining
maintain genome stability
specifically enhance killing
technology description researchers
improved therapeutic strategies
